Growth factor treatment makes no difference to angina class or exercise time in heart patients
This article was originally published in Clinica
Executive Summary
Vascular endothelial growth factor (VEGF) is safe and well-tolerated, but it does not lead to any significant improvement in exercise time or angina class in patients with heart disease who are not suitable for other forms of treatment. These are the results of the first randomised trials that attempted to show that growing small collateral blood vessels can bypass clogged arteries (therapeutic angiogenesis).